Catalyst Pharmaceuticals, Inc.
CPRX
$24.40
$0.160.64%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 19.78% | 25.56% | 28.55% | 29.97% | 23.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.78% | 25.56% | 28.55% | 29.97% | 23.49% |
| Cost of Revenue | 22.66% | 32.08% | -36.44% | -39.89% | -43.84% |
| Gross Profit | 19.20% | 24.32% | 62.50% | 68.71% | 62.09% |
| SG&A Expenses | 9.01% | 5.09% | 12.05% | 17.75% | 32.93% |
| Depreciation & Amortization | 0.32% | 0.77% | 3.16% | 5.65% | 14.78% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.67% | 11.49% | -9.61% | -8.93% | -4.75% |
| Operating Income | 32.11% | 48.74% | 183.45% | 195.38% | 124.77% |
| Income Before Tax | 31.10% | 51.38% | 190.68% | 199.54% | 128.82% |
| Income Tax Expenses | 32.11% | 48.35% | 149.08% | 188.66% | 126.72% |
| Earnings from Continuing Operations | 30.78% | 52.36% | 206.19% | 203.07% | 129.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.78% | 52.36% | 206.19% | 203.07% | 129.50% |
| EBIT | 32.11% | 48.74% | 183.45% | 195.38% | 124.77% |
| EBITDA | 26.94% | 40.27% | 129.68% | 136.03% | 94.58% |
| EPS Basic | 27.01% | 44.41% | 196.96% | 178.13% | 104.98% |
| Normalized Basic EPS | 29.88% | 42.91% | 172.31% | 171.58% | 106.29% |
| EPS Diluted | 29.18% | 45.62% | 205.24% | 190.43% | 114.48% |
| Normalized Diluted EPS | 31.60% | 44.70% | 182.21% | 183.57% | 115.84% |
| Average Basic Shares Outstanding | 3.24% | 5.53% | 7.63% | 9.65% | 11.46% |
| Average Diluted Shares Outstanding | 1.85% | 4.24% | 8.07% | 10.04% | 11.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |